Stock TCON TRACON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights TRACON Pharmaceuticals, Inc.

Equities

TCON

US89237H3084

Delayed Nasdaq
Other stock markets
 11:06:29 2024-06-07 am EDT 		5-day change 1st Jan Change
1.18 USD 0.00% Intraday chart for TRACON Pharmaceuticals, Inc. -7.81% -66.30%
May. 14 TRACON Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 14 Transcript : TRACON Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (TCON) TRACON PHARMACEUTICALS Posts Q1 Revenue $100,000
MT
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
CI
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (TCON) TRACON PHARMACEUTICALS Reports Q4 Revenue $3M, vs. Street Est of $1.5M
MT
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
CI
Tracon Licenses Product Development Platform for $3 Million Upfront Payment; Shares Jump
MT
TRACON Pharmaceuticals, Inc. Announces License of Product Development Platform for $3.0 Million Upfront Payment
CI
Exchange-Traded Funds, Equity Futures Rise After Fed Chief's Comments
MT
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
CI
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
CI
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Tracon Pharmaceuticals Shares Drop After Arbitration Award in I-Mab Dispute
MT
I-Mab Says Tracon Pharmaceuticals Arbitration Ended With 'Positive Outcome'
MT
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TCON Stock
  4. News TRACON Pharmaceuticals, Inc.
  5. Highlights